Meeting
2014 Gastrointestinal Cancers Symposium
Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.
Authors
Gargi Dan Basu
Caris Life Sciences, Phoenix, AZ
Gargi Dan Basu , Joanne Xiu , David Arguello , Rebecca A. Feldman , Sherri Z. Millis , Ryan P. Bender , Zoran Gatalica , Les Paul , Fadi S. Braiteh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 399)
DOI
10.1200/jco.2014.32.3_suppl.399
Abstract #
399
Poster Bd #
A18
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall d’Hebron Institute of Oncology phase I program cohort.
First Author: Enrique Sanz-Garcia
Poster
2014 ASCO Annual Meeting
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
First Author: Eiji Shinozaki
Poster
2014 ASCO Annual Meeting
Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.
First Author: John A. Bridgewater
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel